<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B9555EF4-3FC8-407F-8EA4-861AC1A5E589"><gtr:id>B9555EF4-3FC8-407F-8EA4-861AC1A5E589</gtr:id><gtr:firstName>Cahir</gtr:firstName><gtr:surname>O'Kane</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2313C693-6B5F-4A48-90C5-90D57FC2D64B"><gtr:id>2313C693-6B5F-4A48-90C5-90D57FC2D64B</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Rubinsztein</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ006904%2F1"><gtr:id>36F84E18-DDD0-4723-A218-280CE08E188E</gtr:id><gtr:title>IDENTIFICATION OF GENERIC SUPRESSORS OF PROTEINOPATHIES</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J006904/1</gtr:grantReference><gtr:abstractText>We aim to identify genes that reduce the toxicity of a wide range of different mutant proteins that cause neurodegeneration. We will identify such genes and pathways by performing a bioinformatics analysis of existing genetic screens for modifiers in lower organisms (from yeast to Drosophila), as well as targeted studies in all systems, including high confidence genome wide association study hits for Alzheimer's and Parkinson's disease and ALS. Using multiple data sources, we will identify
hallmark features of &amp;quot;generic modifiers&amp;quot; and use computational methods to identify
new modifiers, which will then be tested for efficacy in fruit fly models of different diseases, like Huntington's disease and forms of dementia. Novel modifiers showing efficacy in more
than one disease will be studied in cell models and fruit flies to identify mechanisms of
action. The identification of such &amp;quot;generic&amp;quot; supressors and their mechanisms would
create a list of high priority targets for consideration for therapeutic development and/or
detailed mechanistic analyses, as these would be acting on a range of diseases and are
expected to affect core processes.</gtr:abstractText><gtr:technicalSummary>We aim to identify &amp;quot;generic&amp;quot; suppressors of neurodegeneration caused by different
intracellular proteinopathies by performing a bioinformatics meta-analysis of existing
genetic screens for modifiers in lower organisms (from yeast to Drosophila), as well as
targeted studies in all systems, including high confidence GWAS hits for Alzheimer's and
Parkinson's disease and ALS. Using multiple data sources, including functional genomics
data, such as protein interaction or mRNA expression profiling data, we will identify
hallmark features of generic modifiers and train machine learning classifiers to identify
new modifiers, which will then be tested for efficacy in Drosophila models of different
proteinopathies (HD, TDP-43, tauopathies). Novel modifiers showing efficacy in more
than one disease will be studied in cell models and Drosophila to identify mechanisms of
action. The identification of such &amp;quot;generic&amp;quot; supressors and their mechanisms would
create a list of high priority targets for consideration for therapeutic development and/or
detailed mechanistic analyses, as these would be acting on a range of diseases and are
expected to affect core processes.</gtr:technicalSummary><gtr:potentialImpactText>The potential beneficiaries of our research include patients with neurodegenerative diseases and their families, clinicians treating these families, other scientists working on neurodegenerative disease, and biotech and pharma companies with interests in these fields. They will benefit if we identify novel pathways regulating neurodegenerative disease, especially if these are druggable. 

This will be of benefit to the pharma/biotech sector, as the identification of novel targets and pathways is a critical first step towards rational therapeutic strategies. This is particularly relevant to neurodegenerative diseases, which are becoming an increasing economic, healthcare, social care, and social burden on societies which are living longer. If we have success with our studies, and if we identify pathways that are relevant to treatment/disease progression, the such programmes would ultimately benefit society at large, and not only the specific patients and their families 

The identification of such pathways may also have relevance to the development of more powerful biomarkers for some of these diseases. This is an area of need, since current clinical trial strategies are handicapped by the need for large patient cohorts, and experimental medicine-type studies using biomarkers may assist in prioritising the potential interventions that should be tested in such large cohorts. The beneficiaries in this context would be clinician-scientists and ultimately patients. 
The staff employed on this project will hopefully acquire a range of relevant scientific and transferable skills (like their predecessors) and be highly employable in various sectors. Staff working in our labs have moved on to good positions in academia (lectureships, senior and intermediate fellowships, postdoc positions at prestigious institutions like Harvard and MIT), as well as good positions in pharma.</gtr:potentialImpactText><gtr:fund><gtr:end>2013-10-11</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>407427</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>15 international conferences in 2016 - speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E0DC8DF1-1E73-4594-8F10-8397B70A806D</gtr:id><gtr:impact>conference presentations at internationa; meetings: Black Forest Winter Conference: &amp;quot;Autophagic Membrane Trafficking &amp;amp; Dynamics in Ageing and Disease&amp;quot; (Freiburg 2016), CHDI's 11th Annual Therapeutics Conference (Palm Springs 2016), International Congress of Human Genetics (Kyoto, 2016), Neuroscience School of Advanced Studies - Autophagy and neuroprotection (Cortona - lecture course 2016), International Society for Developmental Neuroscience (2016, Juan les Pins), European Neuroscience Institute 15th Anniversary Symposium (Gottingen 2016), Keystone Autophagy symposium (Whistler, 2016), Mitochondria: balancing health and disease (London 2016), Nobel conference - The Cell Cycle and Cell Death in Disease (Stockholm, 2016), Centre for Translational Cell Research opening sympiosium (Freiburg 2016), PhD graduate Symposium Cologne Graduate School of Aging Research (2016), Cold Spring Harbor meeting: Neurodegenerative Diseases: Biology &amp;amp; Therapeutics (Cold Spring Harbor 2016), Milner Therapeutics Institute Symposium (Cambridge 2016), 26th Annual Meeting of the Network for European CNS Transplantation &amp;amp; Restoration (NECTAR), Cambridge 2016)</gtr:impact><gtr:outcomeId>5894529ca46787.99751588</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9DDB954B-984E-480A-9E72-71E4C791719D</gtr:id><gtr:impact>More than 200 people at talk, youtube film

interest in field</gtr:impact><gtr:outcomeId>jKhnSkYG9Wh</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A12E2948-0841-45A9-AD36-A6C8F79C2822</gtr:id><gtr:title>The Hedgehog signalling pathway regulates autophagy.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5f2844786e918d6d020121b554ff860"><gtr:id>c5f2844786e918d6d020121b554ff860</gtr:id><gtr:otherNames>Jimenez-Sanchez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13471_21_23149744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E82D101-9CD1-4DB5-B7A0-6EC4EFF5CE38</gtr:id><gtr:title>NeuroGeM, a knowledgebase of genetic modifiers in neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>BMC medical genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5680fc6c80f0ab757d024836c537df54"><gtr:id>5680fc6c80f0ab757d024836c537df54</gtr:id><gtr:otherNames>Na D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1755-8794</gtr:issn><gtr:outcomeId>543ff116602b12.74675864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CB72A50-6BD5-4E2F-879E-7F3B00DD60A7</gtr:id><gtr:title>siRNA screen identifies QPCT as a druggable target for Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5f2844786e918d6d020121b554ff860"><gtr:id>c5f2844786e918d6d020121b554ff860</gtr:id><gtr:otherNames>Jimenez-Sanchez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>doi_55faa2aa247591b4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5ECE338-923C-4686-A01F-11839ABF6E65</gtr:id><gtr:title>Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68d9bd81131c2ef85da0b3bb510c1948"><gtr:id>68d9bd81131c2ef85da0b3bb510c1948</gtr:id><gtr:otherNames>Menzies FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>543ff1e645f401.92798788</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J006904/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>